Search

Your search keyword '"Valenti, Luca"' showing total 246 results

Search Constraints

Start Over You searched for: Author "Valenti, Luca" Remove constraint Author: "Valenti, Luca" Journal journal of hepatology Remove constraint Journal: journal of hepatology
246 results on '"Valenti, Luca"'

Search Results

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

3. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models

4. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease

5. A global research priority agenda to advance public health responses to fatty liver disease

6. TOP-301 Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease

7. FRI-290 Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness

9. WED-293 Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease

11. WED-130 Prevalence and predictors of porto-sinusoidal vascular disorder in patients with persistent and unexplained gamma-glutamyl transferase elevation: a multicenter study

13. TOP-144-YI Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease

14. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

15. Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19]

16. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

17. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease

18. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

20. Evaluation of Google search trends for liver diseases in Europe

21. A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced NAFLD: first report

22. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

23. Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers

24. High diagnostic uptake of a targeted panel sequencing in adult patients with chronic hereditary liver disorders

25. Predictors of liver stiffness changes in consecutive cohorts of patients with non-alcoholic fatty liver disease and longitudinal follow-up

26. MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents

27. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

28. Burden of non-alcoholic fatty liver disease and usefulness of non-invasive tests to identify advanced liver disease in patients with type 2 diabetes mellitus: interim analysis of an Italian prospective multicentre study

29. Abdominal adiposity and insulin resistance are the main predictors of CAP values in individuals with metabolic dysfunction: the liver-bible cohort

30. A functional interaction between hepatic estrogen receptor-α and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women

31. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]

32. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

33. Statin use and non-alcoholic steatohepatitis in at risk individuals

35. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

37. Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study

38. Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease

39. Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC

40. SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD

41. Senescence, hand in hand with hepatic iron overload during the progression of NAFLD

43. Transcriptomic analysis confirms that PNPLA3 I148M variant is associated with impaired mitochondrial function and antioxidant response in 3D cultured human hepatic stellate cells and liver tissue of patients with NAFLD

44. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results form a genome-wide case-control study

45. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

47. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

48. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

49. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD

50. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Catalog

Books, media, physical & digital resources